ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Director Holdings

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that following admission of the second tranche of new common shares at 8.00 a.m. on 22 November 2024 in relation to the Fundraising, the directors' interests in the Company are as follows:

¹ Existing beneficial holding includes 118,091,377 shares held by Carolyn Cross, including via holdings in 100% owned companies, and 37,772,652 shares held by Robert Cross, husband of Carolyn Cross.

-Ends-

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.